A Tohoku University team just won $1 million in a global healthspan prize for particles engineered to hunt down the cells that make us old.
Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what stands between them and the competition’s final phase.
Keisuke Goda has spent years thinking about a strange design flaw in the human body: some of our cells refuse to die when they should. They just sit there, doing damage. Now his lab thinks it has found a way to send in a fix, and the judges of one of the largest health research competitions on the planet agree it is worth a serious look.
Goda, who leads a research team at the SiRIUS Institute of Medical Research and Graduate School of Medicine at Tohoku University, working alongside chemists at the University of Tokyo, has just been named a Milestone 2 Awardee of the XPRIZE Healthspan competition [1]. The team was chosen from a field of more than 600 entrants worldwide and collects a $1 million award to fund further testing.
To understand why that matters, it helps to know what the team is targeting: senescent cells. These are cells that have stopped dividing but, instead of clearing out of the body the way they are supposed to, stick around. Scientists have increasingly linked their buildup to the aches, slowdowns, and diseases that come with age. Think of them less as dead weight and more as cells stuck on an old shift, still clocked in long after they should have gone home, quietly wearing down everything around them.
Clearing them out has become one of longevity science’s most active pursuits. Goda’s lab has taken an unusual route: rather than killing senescent cells outright, his team built a delivery system to repair the tissue around them.
The tool is something the researchers call a “super exosome.” Exosomes are naturally occurring particles that cells already use to ferry material to one another – nature’s own courier service. Goda’s team modified the surface of these particles with lanthanide ions, a chemistry tweak that dramatically sharpens their ability to home in on senescent cells specifically. Once attached, the particles unload their cargo: growth factors and genetic material aimed at repairing the surrounding tissue.
In mice, across multiple aged cohorts, the effect showed up in measurable ways: improved frailty scores, better physical performance, and gains across several other markers researchers use to track age-related decline, all without raising safety concerns. Using standard methods for translating results between species, the team estimates the benefit could correspond to more than 15 additional healthy years in humans. That is an early, mouse-derived projection, not a guarantee. The real test starts now.
Next stop: human trials
To find out whether the projection holds, the team is moving into clinical studies with Tohoku University Hospital and the university’s Healthspan Research Center. The bar they need to clear for the XPRIZE Grand Prize is steep: proof that the therapy extends healthy human lifespan by at least ten years.
If the science holds up outside of mice, the lab believes the same delivery platform could reach well beyond frailty – into cognitive and immune function, hair regeneration, skin rejuvenation and reproductive medicine. Commercialization plans are already taking shape through a venture called NanoTitan, which would handle manufacturing and distribution of any resulting therapies out of Japan.
Goda frames the milestone as a step, not a finish line.
“Advancing to the XPRIZE Healthspan finals is an important milestone, but our ultimate goal is to translate this technology into therapies that allow people to lead healthy, independent, and active lives longer,” he told Asia Research News. “We look forward to validating this approach in human clinical studies and bringing its benefits to society.”
What makes this story worth watching isn’t just the prize money; it’s what the approach represents. Much of longevity research has chased ways to kill off senescent cells outright. Goda’s team is testing a different bet: leave the damaged cells be, but flood the surrounding tissue with the raw materials to repair itself. If that logic holds up in people the way it did in mice, it could open a second front in how the field tackles aging tissue, one aimed less at demolition and more at repair.
